Search results for " OPIOIDS"

showing 10 items of 23 documents

Low doses of transdermal fentanyl in opioid-naive patients with cancer pain.

2010

The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) fentanyl patches in opioid-naive patients with cancer pain.This was a nonrandomized, open-label, uncontrolled study in fifty consecutive opioid-naive patients with advanced cancer and moderate pain. TD fentanyl was initiated at a dose of 12 µg/h. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD fentanyl doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated.Thirty-one patients completed all 4 weeks of the study. Pain control was achieved within a me…

MaleTransdermal patchCancer pain; Opioids; Trandermal fentanyl; Aged; Analgesia; Analgesics Opioid; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoadjuvant Therapy; Neoplasms; Pain; Palliative Care; Transdermal Patch; Medicine (all)medicine.medical_treatmentPainTransdermal PatchOpioidFentanylDose-Response RelationshipNeoplasmsmedicineHumansCancer painAdverse effectNeoadjuvant therapyTransdermalAgedAnalgesicsDose-Response Relationship Drugbusiness.industryMedicine (all)Palliative CareGeneral MedicineMiddle AgedNeoadjuvant TherapyOpioidsClinical trialAnalgesics OpioidFentanylTolerabilityTrandermal fentanylAnesthesiaFemaleDrugAnalgesiaCancer painbusinessmedicine.drugCurrent medical research and opinion
researchProduct

Low doses of transdermal buprenorphine in opioid-naive patients with cancer pain: A 4-week, nonrandomized, open-label, uncontrolled observational stu…

2009

OBJECTIVE: The aim of this study was to evaluate the effect and tolerability of low doses of transdermal (TD) buprenorphine patches in opioid-naive patients with cancer pain. METHODS: This was a nonrandomized, open-label, uncontrolled study in consecutive opioid-naive patients with advanced cancer and moderate pain. TD buprenorphine was initiated at a dose of 17.5 microg/h (0.4 mg/d), with patch changes every 3 days. Doses were then adjusted according to the clinical response. Pain intensity, opioid-related adverse effects, TD buprenorphine doses, and quality of life were monitored over 4 weeks. The time to dose stabilization and indexes of dose escalation were also calculated. RESULTS: Thi…

Malecancer painPainOpioidUncontrolled Studytransdermal buprenorphine cancer pain uncontrolled observational studyDose-Response RelationshipNeoplasmsmedicineHumansPharmacology (medical)Adverse effectAgedPain MeasurementIntractablePharmacologyAnalgesicsbusiness.industryopioidsCancermorphineMiddle Agedbuprenorphine; cancer pain; morphine; opioids; Administration Cutaneous; Aged; Analgesics Opioid; Buprenorphine; Dose-Response Relationship Drug; Female; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Pain Intractable; Quality of Life; Pharmacology; Pharmacology (medical)buprenorphinemedicine.diseaseClinical trialCutaneousTolerabilityAnesthesiaAdministrationQuality of LifeMorphineFemaleDrugCancer painbusinessmedicine.drugBuprenorphineClinical Therapeutics
researchProduct

Safety and effectiveness of intravenous morphine for episodic breakthrough pain in patients receiving transdermal buprenorphine.

2006

Supplemental dosing of an opioid is the main treatment suggested to manage breakthrough pain in cancer patients. The intravenous route has been proven to be safe and effective, providing rapid analgesia in patients receiving oral morphine. Transdermal buprenorphine (TTS-BUP) is increasingly used in cancer pain management, but this drug has been labeled as a difficult drug to use in combination with other opioids. The aim of this open-label study was to verify the safety and effectiveness of intravenous morphine (IV-MO) for the treatment of episodic pain in cancer patients receiving TTS-BUP. A consecutive sample of 29 cancer patients, who were treated with TTS-BUP, reported an acceptable bas…

Malecancer painPalliative careExacerbationtransdermal buprenorphinePainOpioidAdministration CutaneousInjectionsNeoplasmsmedicineSecondary PreventionHumansepisodic breakthrough painDosingAdverse effectbreakthrough pain; cancer pain; Intravenous morphine; opioids; transdermal buprenorphine; Administration Cutaneous; Analgesics Opioid; Buprenorphine; Drug Combinations; Female; Humans; Injections Intravenous; Male; Middle Aged; Morphine; Neoplasms; Pain; Pain Measurement; Palliative Care; Secondary Prevention; Treatment Outcome; Anesthesiology and Pain Medicine; Neurology (clinical); Neurology; Nursing (all)2901 Nursing (miscellaneous)Nursing (all)2901 Nursing (miscellaneous)General NursingPain MeasurementAnalgesicsMorphinebusiness.industryPalliative CareopioidsIntravenous morphineMiddle Agedbreakthrough painBuprenorphineAnalgesics Opioidtransdermal buprenorphine.Drug CombinationsCutaneousAnesthesiology and Pain MedicineTreatment OutcomeNeurologyOpioidAnesthesiaAdministrationInjections IntravenousMorphineFemaleNeurology (clinical)IntravenousCancer painbusinesssafety and effectiveness of intravenous morphinemedicine.drugBuprenorphineJournal of pain and symptom management
researchProduct

Breakthrough pain in patients with abdominal cancer pain.

2014

Abstract OBJECTIVE: Characterization of breakthrough cancer pain (BTcP) in patients with abdominal cancer is lacking. The aim of this study was to assess the characteristics of BTcP in patients with abdominal cancer pain. PATIENTS AND METHODS: In an observational cohort study, from a consecutive sample of patients admitted to a pain relief and supportive care unit for a period of 13 months, patients with abdominal disease due to cancer, including primary cancer or metastases, were assessed for the presence of chronic abdominal pain; its mechanism, intensity of background pain, and pain flares, which were distinguishable from the baseline pain, were recorded. Patients presenting with pain fl…

Malecancer painmedicine.medical_specialtyPalliative careAnalgesicSettore MED/41 - AnestesiologiaDiseaseSettore MED/42 - Igiene Generale E ApplicataCohort StudiesNeoplasmsInternal medicinemedicineHumansPain ManagementIn patientcancer pain; breakthrough pain; abdominal pain; epidemiology; opioidsNeoplasm MetastasisAgedPain MeasurementAnalgesicsbusiness.industryPalliative Careabdominal painopioidsCancerbreakthrough painmedicine.diseaseAnesthesiology and Pain MedicineFemaleepidemiologyObservational studyNeurology (clinical)Chronic PainCancer painbusinessCohort study
researchProduct

Relationship between background cancer pain, breakthrough pain, and analgesic treatment: a preliminary study for a better interpretation of epidemiol…

2020

Abstract Abstract Background: The different operational definitions of breakthrough cancer pain (BTcP) has generated unclear epidemiological data. Methods: A consecutive sample of patients was categorized on the basis of their background pain intensity, background analgesic treatment, and the presence of BTcP. Results: A total of 265 patients were surveyed; 117 patients had background pain and 91 patients presented peaks of pain intensity distinguishable from background pain. Of 117 patients with background pain, 49 patients were re-assessed after optimization of background analgesia (T1) within a mean of 8.2 days. Pain intensity significantly decreased in comparison with values recorded at…

Malemedicine.medical_specialtyEpidemiologyBreakthrough PainAnalgesicOpioidSettore MED/42 - Igiene Generale E ApplicataCONSECUTIVE SAMPLENeoplasmsSurveys and QuestionnairesEpidemiologyMedicineHumansPain ManagementCancer painPain MeasurementAnalgesicsbackground cancer painbusiness.industryMedicine (all)General MedicineBreakthrough pain; Cancer pain; Epidemiology; Opioids; Analgesics Opioid; Breakthrough Pain; Female; Humans; Male; Neoplasms; Pain Management; Pain Measurement; Surveys and Questionnaires; Medicine (all)breakthrough painIntensity (physics)OpioidsAnalgesics OpioidAnesthesiaepidemiologic studyFemaleCancer painbusinessbackground cancer pain; breakthrough pain; epidemiologic study
researchProduct

Equipotent doses to switch from high doses of opioids to transdermal buprenorphine.

2008

INTRODUCTION: The aim of this study was to evaluate the equianalgesic ratio of transdermal buprenorphine (TD BUP) with oral morphine and TD fentanyl in a sample of consecutive cancer patients receiving stable doses of 120-240 mg of oral morphine or 50-100 microg of TD fentanyl, reporting adequate pain and symptom control. MATERIALS, METHODS, AND RESULTS: Patients receiving daily stable doses of opioids for more than 6 days, with no more than two doses of oral morphine (20 and 40 mg, respectively) as needed, were switched to TD BUP using a fentanyl-BUP ratio of 0.6:0.8 and an oral morphine-BUP ratio of 70:1. Opioid doses, pain and symptom intensity, global satisfaction, and number of breakth…

Maletransdermal buprenorphinePainAdministration CutaneousFentanylNeoplasmsHigh dosesMedicineHumansSymptom controlProspective StudiesOral morphineAgedDose-Response Relationship Drugbusiness.industryMiddle AgedEquianalgesicBuprenorphineAnalgesics OpioidFentanylOncologyPatient SatisfactionAnesthesiaFemaleTransdermal Buprenorphinehigh doses of opioidsbusinessCancer painmedicine.drugSupportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
researchProduct

Dosing fentanyl buccal tablet for breakthrough cancer pain: dose titration versus proportional doses.

2012

Abstract OBJECTIVES: The aim of this study was to compare the efficacy and safety of doses of fentanyl buccal tablet (FBT) proportional to doses of opioids used for background analgesia versus dose titration starting with the minimal dose for the management of breakthrough cancer pain (BTcP). METHODS: A total of 82 cancer patients with BTcP who were receiving strong opioids in doses of at least 60 mg of oral morphine equivalents and having acceptable background analgesia, were selected for a multicenter unblinded study. Forty-one patients were randomized to receive FBT in doses proportional to the daily opioid doses for four consecutive episodes of BTcP (group P). Forty-one patients underwe…

OralMaleDose titrationfentanyl buccal tabletAdministration OralOpioidDosing fentanylSettore MED/42 - Igiene Generale E ApplicataDose titrationlaw.inventionDose-Response RelationshipRandomized controlled triallawNeoplasmsFentanyl Buccal TabletMedicineHumansRapid onset opioidsDrug Dosage CalculationsCancer painAgedPain MeasurementAnalgesicsDose-Response Relationship DrugBreakthrough pain; Cancer pain; Dose titration; Fentanyl buccal tablet; Rapid onset opioids; Administration Oral; Aged; Analgesics Opioid; Breakthrough Pain; Dose-Response Relationship Drug; Female; Fentanyl; Humans; Male; Middle Aged; Neoplasms; Pain Measurement; Tablets; Titrimetry; Drug Dosage Calculations; Medicine (all)business.industryMedicine (all)Breakthrough PainTitrimetryCancerGeneral MedicineBuccal administrationfentanyl buccal tablet; breakthrough cancer pain; randomized clinical trialMiddle Agedmedicine.diseaserandomized clinical trialAnalgesics OpioidFentanylbreakthrough cancer painOpioidAnesthesiaAdministrationFemaleDrugbusinessCancer painmedicine.drugTabletsCurrent medical research and opinion
researchProduct

The stigma of low opioid prescription in the hospitalized multimorbid elderly in Italy.

2015

The primary aim of this study was to evaluate the prevalence of opioid prescriptions in hospitalized geriatric patients. Other aims were to evaluate factors associated with opioid prescription, and whether or not there was consistency between the presence of pain and prescription. Opioid prescriptions were gathered from the REgistro POliterapie Societa` Italiana di Medicina Interna (REPOSI) data for the years 2008, 2010 and 2012. 1,380 in-patients, 65+ years old, were enrolled in the first registry run, 1,332 in the second and 1,340 in the third. The prevalence of opioid prescription was calculated at hospital admission and discharge. In the third run of the registry, the degree of pain was…

RegistrieMalePoison controlOlder personComorbidityPractice PatternsDrug PrescriptionOlder persons Pain Analgesic opioids80 and overRegistriesPractice Patterns Physicians'Pain MeasurementAged 80 and overAnalgesicsAnalgesic opioids; Older persons; Pain; Emergency Medicine; Internal MedicineAnalgesics OpioidHospitalizationItalyEmergency MedicineFemaleTramadolHumanmedicine.drugmedicine.medical_specialtyAttitude of Health PersonnelAnalgesicPainOpioidelderlyDrug PrescriptionsInjury preventionmedicineInternal MedicineHumansAnalgesic opioidsMedical prescriptionAgedPhysicians'business.industryCodeineSettore MED/09 - MEDICINA INTERNAAnalgesic opioidmedicine.diseaseComorbidityOlder persons Pain Analgesic opioidsOpioidOlder personsEmergency medicinebusinessAnalgesic opioids; Older persons; Pain; Aged; Aged 80 and over; Analgesics Opioid; Comorbidity; Drug Prescriptions; Female; Humans; Italy; Male; Pain; Pain Measurement; Practice Patterns Physicians'; Registries; Attitude of Health Personnel; Hospitalization; Internal Medicine; Emergency MedicineAnalgesic opioids; Older persons; Pain; Aged; Aged 80 and over; Analgesics Opioid; Comorbidity; Drug Prescriptions; Female; Humans; Italy; Male; Pain; Pain Measurement; Practice Patterns Physicians'; Registries; Attitude of Health Personnel; Hospitalization; Emergency Medicine; Internal Medicine
researchProduct

Fentanyl and sufentanyl in fast track anaesthesia for major intra-abdominal surgery

2012

Background and aim: Major intra-abdominal surgery is estimated to have high costs annually in Italy. In an attempt to decrease surgery costs and improve outcome for patients, fast-track programs have become popular. This is especially due both to the improvement of surgery and to the new anesthetic agents (regarding pharmacokinetic and pharmacodynamic) resulting in better care for patients. The aim of this study was to evaluate two different anesthetic protocols in patients undergoing scheduled anesthesia including the combination of two different opioids (fentanyl or sufentanil) with the same hypnotic and muscle relaxant. Material and Methods: 40 patients, with an American Society of Anest…

Settore MED/18 - Chirurgia GeneraleSettore MED/41 - AnestesiologiaFAST TRACK ANAESTHESIA OPIOIDS INTRAABDOMINAL SURGERY ICU LENGTH OF STAY HOSPITAL LENGTH OF STAY
researchProduct

Effects of transdermal buprenorphine on patients-reported outcomes in cancer patients: results from the Cancer Pain Outcome Research (CPOR) Study Gro…

2009

cancer pain opioids
researchProduct